Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Blinded, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of BIIB132 Administered Intrathecally to Adults With Spinocerebellar Ataxia 3

NCT05160558 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT05160558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05160558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Blinded, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of BIIB132 Administered Intrathecally to Adults With Spinocerebellar Ataxia 3
Lead sponsor
Biogen
Phase
Phase 1
Overall status
Terminated
Start date
February 2, 2022
Completion date
July 25, 2023
Enrollment
8 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

spinocerebellar ataxia type 3